2019
Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study
MIRAVITLLES, Marc, Vladimir KOBLIZEK, Cristina ESQUINAS, Branislava MILENKOVIC, Adam BARCZYK et. al.Základní údaje
Originální název
Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study
Autoři
MIRAVITLLES, Marc (724 Španělsko, garant), Vladimir KOBLIZEK (203 Česká republika), Cristina ESQUINAS (724 Španělsko), Branislava MILENKOVIC (688 Srbsko), Adam BARCZYK (616 Polsko), Ruzena TKACOVA (703 Slovensko), Attila SOMFAY (348 Maďarsko), Kirill ZYKOV (643 Rusko), Neven TUDORIC (191 Chorvatsko), Kosta KOSTOV (100 Bulharsko), Zuzana ZBOŽÍNKOVÁ (203 Česká republika, domácí), Michal SVOBODA (203 Česká republika, domácí), Jurij SORLI (705 Slovinsko), Alvils KRAMS (428 Lotyšsko) a Arschang VALIPOUR (40 Rakousko)
Vydání
RESPIRATORY MEDICINE, LONDON, W B SAUNDERS CO LTD, 2019, 0954-6111
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.095
Kód RIV
RIV/00216224:14110/19:00110576
Organizační jednotka
Lékařská fakulta
UT WoS
000463627700022
Klíčová slova anglicky
COPD; CAT; mMRC; Comorbidities; GOLD classification
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 4. 9. 2019 15:03, Mgr. Tereza Miškechová
Anotace
V originále
Background: The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants. Methods: The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT and modified Medical Research Council (mMRC) scores when used to classify patients according to the GOLD strategy. Results: The study included 3452 patients (69.2% men, mean forced expiratory volume in 1 s (FEV1% predicted) 52.5%). The mean CAT score was 17.5 (SD = 7.8), ranging from 15.1 in Hungary to 21.2 in Bulgaria. Multiple linear regression analysis showed six variables significantly associated with CAT scores: depression, number of previous exacerbations, 6-min walking distance, FEV1(%), mMRC and country and explained 47.2% of the variance of CAT. According to either CAT or mMRC, up to 23.9% patients would be classified in different GOLD groups. Conclusions: The CAT score may be predicted by factors related to COPD severity, depression and exercise capacity, with significant differences in the distribution of CAT scores in different countries. According to our results CAT > 10 is not equivalent to mMRC > 2 for assessing symptom burden.